A randomized, double-blind, two-way cross-over study evaluating systemic bioavailability and airway clearance of SymbicortTurbuhaler 320/9mcg (budesonide/formoterol) vs SeretideDiskus 50/500mcg (salmeterol/fluticasone propionate) after single inhalations in patients with COPD and healthy volunteers

Trial Profile

A randomized, double-blind, two-way cross-over study evaluating systemic bioavailability and airway clearance of SymbicortTurbuhaler 320/9mcg (budesonide/formoterol) vs SeretideDiskus 50/500mcg (salmeterol/fluticasone propionate) after single inhalations in patients with COPD and healthy volunteers

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Apr 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top